Killer Cell Lectin-like Receptor Subfamily G, Member 1 (KLRG1) is a type II transmembrane protein that plays a crucial role in the immune system. It is predominantly expressed on natural killer (NK) cells and certain T cells, where it functions as an inhibitory receptor. The human recombinant form of KLRG1 is a synthesized version of this protein, used in various research and therapeutic applications.
The KLRG1 gene is located on chromosome 12 in humans and encodes a protein that belongs to the killer cell lectin-like receptor (KLR) family . This family comprises transmembrane proteins that are primarily expressed in NK cells. The KLRG1 protein has a lectin-like domain that allows it to bind to specific carbohydrate structures on target cells .
KLRG1 functions as an inhibitory receptor, playing a critical role in regulating the effector functions and developmental processes of NK cells and T cells . It binds to non-MHC ligands such as E-cadherin, N-cadherin, and R-cadherin, which are markers of epithelial and mesenchymal cells . This binding inhibits NK cell-mediated cytotoxicity and interferon-gamma secretion, thereby modulating the immune response .
The role of KLRG1 in immune regulation has significant implications for various diseases, including cancer and infectious diseases. Targeting KLRG1 and other co-inhibitory receptors has gained interest in oncology for enhancing immune activation against tumors . Additionally, KLRG1 knockout mice have shown enhanced immunity in certain disease models, highlighting its potential as a therapeutic target .
The human recombinant form of KLRG1 is used in research to study its function and interactions with ligands. It is also utilized in developing therapeutic strategies aimed at modulating immune responses. By understanding the mechanisms of KLRG1, researchers can design interventions to enhance or inhibit its activity, depending on the desired outcome.